{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,29]],"date-time":"2026-09-29T22:25:32Z","timestamp":1790720732102,"version":"4.1.0"},"reference-count":18,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2024,11,25]],"date-time":"2024-11-25T00:00:00Z","timestamp":1732492800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2024,11,25]],"date-time":"2024-11-25T00:00:00Z","timestamp":1732492800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/100016263","name":"Penn Mental Health AIDS Research Center","doi-asserted-by":"publisher","award":["P30 MH097488"],"award-info":[{"award-number":["P30 MH097488"]}],"id":[{"id":"10.13039\/100016263","id-type":"DOI","asserted-by":"publisher"}]},{"name":"NIDA K12 Yale DAHRS Program","award":["2K12DA033312-11"],"award-info":[{"award-number":["2K12DA033312-11"]}]},{"DOI":"10.13039\/100000025","name":"NIMH","doi-asserted-by":"crossref","award":["K23 MH119976-01A1"],"award-info":[{"award-number":["K23 MH119976-01A1"]}],"id":[{"id":"10.13039\/100000025","id-type":"DOI","asserted-by":"crossref"}]},{"name":"NIDA","award":["K23 DA045085"],"award-info":[{"award-number":["K23 DA045085"]}]},{"name":"NIDA","award":["K23 DA048987"],"award-info":[{"award-number":["K23 DA048987"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Harm Reduct J"],"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n                <jats:title>Background<\/jats:title>\n                <jats:p>Medications for opioid use disorder (MOUD) are under-prescribed to adolescents and young adults (AYA). Few published studies have explored challenges to and opportunities to enhance continuous provision of MOUD for AYA. Our report focuses on this emergent theme that was identified as part of a larger qualitative study.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Methods<\/jats:title>\n                <jats:p>We purposively sampled and enrolled medical providers who prescribed MOUD to AYA. Semi-structured individual interviews using chart-stimulated recall explored barriers and facilitators to MOUD retention. We used modified grounded theory in our qualitative analysis, with double coding of interviews.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Results<\/jats:title>\n                <jats:p>Barriers to retention on MOUD included patient-level (i.e., return to substance use) and system-level factors (i.e., cost, delayed receipt, pharmacy challenges, and in-person visit requirements). Facilitators included patient-level (i.e., motivation, support networks) and system-level factors (i.e., telehealth access, availability of certified recovery specialists).<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Conclusions<\/jats:title>\n                <jats:p>Our study is the first to look at <jats:italic>retention<\/jats:italic> for this key age group, setting it apart from the existing body of literature that looks at medication <jats:italic>initiation<\/jats:italic>. Our findings confirm that significant systemic barriers exist to AYA patients\u2019 retention on MOUD. Further research is needed to develop interventions that facilitate continuous delivery of high-quality care among this key population.<\/jats:p>\n              <\/jats:sec>","DOI":"10.1186\/s12954-024-01113-8","type":"journal-article","created":{"date-parts":[[2024,11,25]],"date-time":"2024-11-25T02:01:04Z","timestamp":1732500064000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":4,"title":["Opportunities to enhance retention on medication for opioid use disorder for adolescents and young adults: results from a qualitative study with medical providers in Philadelphia, PA"],"prefix":"10.1186","volume":"21","author":[{"given":"Maria Christina","family":"Herrera","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kaja","family":"Darien","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sarah","family":"Wood","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Scott E.","family":"Hadland","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J.","family":"Deanna Wilson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nadia","family":"Dowshen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2024,11,25]]},"reference":[{"key":"1113_CR1","unstructured":"Baumgartner JC, Gumas ED, Gunja MZ. Too many lives lost: overdose mortality rates and policy solutions | Commonwealth Fund. To the Point (blog), Commonwealth Fund."},{"issue":"3","key":"1113_CR2","doi-asserted-by":"publisher","first-page":"632","DOI":"10.1016\/j.jadohealth.2020.12.129","volume":"68","author":"LJ Waldron","year":"2021","unstructured":"Waldron LJ, Dakessian S. Medication for adolescents and young adults with opioid use disorder. The society for adolescent health and medicine. J Adolescent Health. 2021;68(3):632\u20136.","journal-title":"J Adolescent Health"},{"issue":"3","key":"1113_CR3","doi-asserted-by":"publisher","first-page":"e20161893","DOI":"10.1542\/peds.2016-1893","volume":"138","author":"SA Ryan","year":"2016","unstructured":"Ryan SA, Gonzalez PK, Patrick SW, Quigley J, Siqueira L, Walker LR. Committee on substance use and prevention. Medication-assisted treatment of adolescents with opioid use disorders. Pediatrics. 2016;138(3):e20161893.","journal-title":"Pediatrics"},{"key":"1113_CR4","doi-asserted-by":"crossref","unstructured":"The ASAM National Practice Guideline for the Treatment of Opioid Use Disorder: 2020 Focused Update. J Addict Med. 2020 Mar\/Apr;14(2S Suppl 1):1\u201391.","DOI":"10.1097\/ADM.0000000000000633"},{"key":"1113_CR5","doi-asserted-by":"publisher","DOI":"10.1016\/j.jsat.2021.108329","volume":"126","author":"N Krawczyk","year":"2021","unstructured":"Krawczyk N, Williams AR, Saloner B, Cerd\u00e1 M. Who stays in medication treatment for opioid use disorder? A national study of outpatient specialty treatment settings. J Subst Abuse Treat. 2021;126: 108329.","journal-title":"J Subst Abuse Treat"},{"issue":"357","key":"1113_CR6","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.j1550","volume":"26","author":"L Sordo","year":"2017","unstructured":"Sordo L, Barrio G, Bravo MJ, Indave BI, Degenhardt L, Wiessing L, Ferri M, Pastor-Barriuso R. Mortality risk during and after opioid substitution treatment: systematic review and meta-analysis of cohort studies. BMJ. 2017;26(357): j1550.","journal-title":"BMJ"},{"issue":"22","key":"1113_CR7","doi-asserted-by":"publisher","first-page":"1983","DOI":"10.1001\/jama.2023.6266","volume":"329","author":"C King","year":"2023","unstructured":"King C, Beetham T, Smith N, et al. Treatments used among adolescent residential addiction treatment facilities in the US, 2022. JAMA. 2023;329(22):1983\u20135.","journal-title":"JAMA"},{"issue":"2","key":"1113_CR8","doi-asserted-by":"publisher","DOI":"10.1542\/peds.2022-058755","volume":"151","author":"A Terranella","year":"2023","unstructured":"Terranella A, Guy GP, Mikosz C. Buprenorphine dispensing among youth aged \u226419 years in the United States: 2015\u20132020. Pediatrics. 2023;151(2): e2022058755.","journal-title":"Pediatrics"},{"issue":"4","key":"1113_CR9","doi-asserted-by":"publisher","first-page":"542","DOI":"10.1016\/j.jadohealth.2020.03.005","volume":"67","author":"RH Alinsky","year":"2020","unstructured":"Alinsky RH, Hadland SE, Matson PA, Cerda M, Saloner B. Adolescent-serving addiction treatment facilities in the united states and the availability of medications for opioid use disorder. J Adolesc Health. 2020;67(4):542\u20139.","journal-title":"J Adolesc Health"},{"key":"1113_CR10","doi-asserted-by":"publisher","DOI":"10.1097\/ADM.0000000000001195","author":"MC Herrera","year":"2023","unstructured":"Herrera MC, et al. A qualitative study of barriers and facilitators to integrating medications for opioid use disorder and HIV preexposure prophylaxis for adolescents and young adults. J Addict Med. 2023. https:\/\/doi.org\/10.1097\/ADM.0000000000001195.","journal-title":"J Addict Med"},{"issue":"4","key":"1113_CR11","first-page":"228","volume":"34","author":"AC Feldstein","year":"2008","unstructured":"Feldstein AC, Glasgow RE. A practical, robust implementation and sustainability model (PRISM) for integrating research findings into practice. Jt Comm J Qual Patient Saf. 2008;34(4):228\u201343.","journal-title":"Jt Comm J Qual Patient Saf"},{"issue":"9","key":"1113_CR12","doi-asserted-by":"publisher","first-page":"1245","DOI":"10.1097\/ACM.0000000000000388","volume":"89","author":"BC O\u2019Brien","year":"2014","unstructured":"O\u2019Brien BC, Harris IB, Beckman TJ, Reed DA, Cook DA. Standards for reporting qualitative research: a synthesis of recommendations. Acad Med. 2014;89(9):1245\u201351.","journal-title":"Acad Med"},{"issue":"50","key":"1113_CR13","doi-asserted-by":"publisher","first-page":"1576","DOI":"10.15585\/mmwr.mm7150a2","volume":"71","author":"LJ Tanz","year":"2022","unstructured":"Tanz LJ, et al. Drug overdose deaths among persons aged 10\u201319 years-United States, July 2019-December 2021. Morbid Mortal Weekly Rep. 2022;71(50):1576.","journal-title":"Morbid Mortal Weekly Rep"},{"issue":"1","key":"1113_CR14","doi-asserted-by":"publisher","first-page":"e2022057992","DOI":"10.1542\/peds.2022-057992","volume":"150","author":"DR Camenga","year":"2022","unstructured":"Camenga DR, Hammer LD. The Committee on Substance Use and Prevention, and Committee on Child Health Financing; Improving Substance Use Prevention, Assessment, and Treatment Financing to Enhance Equity and Improve Outcomes Among Children, Adolescents, and Young Adults. Pediatrics. 2022;150(1):e2022057992. https:\/\/doi.org\/10.1542\/peds.2022-057992.","journal-title":"Pediatrics"},{"issue":"11","key":"1113_CR15","doi-asserted-by":"publisher","first-page":"1029","DOI":"10.1001\/jamapediatrics.2018.2143","volume":"172","author":"SE Hadland","year":"2018","unstructured":"Hadland SE, et al. Receipt of timely addiction treatment and association of early medication treatment with retention in care among youths with opioid use disorder. JAMA Pediatr. 2018;172(11):1029\u201337.","journal-title":"JAMA Pediatr"},{"issue":"14","key":"1113_CR16","doi-asserted-by":"publisher","first-page":"1289","DOI":"10.1056\/NEJMp1917360","volume":"382","author":"ND Volkow","year":"2020","unstructured":"Volkow ND. Stigma and the toll of addiction. N Engl J Med. 2020;382(14):1289\u201390.","journal-title":"N Engl J Med"},{"key":"1113_CR17","unstructured":"Consolidated Appropriations Act.; 2023. Accessed August 30, 2024. https:\/\/www.appropriations.senate.gov\/imo\/media\/doc\/JRQ121922.PDF"},{"issue":"6","key":"1113_CR18","doi-asserted-by":"publisher","first-page":"667","DOI":"10.1016\/j.jadohealth.2017.12.012","volume":"62","author":"DL Spencer","year":"2018","unstructured":"Spencer DL, McManus M, Call KT, Turner J, Harwood C, White P, Alarcon G. Health care coverage and access among children, adolescents, and young adults, 2010\u20132016: Implications for future health reforms. J Adolesc Health. 2018;62(6):667\u201373.","journal-title":"J Adolesc Health"}],"container-title":["Harm Reduction Journal"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12954-024-01113-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12954-024-01113-8\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12954-024-01113-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,11,25]],"date-time":"2024-11-25T14:04:44Z","timestamp":1732543484000},"score":1,"resource":{"primary":{"URL":"https:\/\/harmreductionjournal.biomedcentral.com\/articles\/10.1186\/s12954-024-01113-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,11,25]]},"references-count":18,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2024,12]]}},"alternative-id":["1113"],"URL":"https:\/\/doi.org\/10.1186\/s12954-024-01113-8","relation":{},"ISSN":["1477-7517"],"issn-type":[{"value":"1477-7517","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,11,25]]},"assertion":[{"value":"14 February 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"28 October 2024","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"25 November 2024","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This study was approved by the Children\u2019s Hospital of Philadelphia Institutional Review Board. All participants completed an informed consent process with study staff that detailed the study purpose, protocol, and potential risks and benefits.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"The authors declare no competing interests.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"210"}}